

# Special Issue

## MAPK in Cancers: From Signalling Pathways to Therapeutic Targets

### Message from the Guest Editor

The mitogen-activated protein kinase (MAPK) is an evolutionary-conserved signaling cascade that plays a crucial role in cell signal transduction in response to a range of extracellular and intracellular stimuli, both in physiological and pathological conditions. The MAPK/ERK pathway is the best studied of the mammalian MAPK pathways, and it is dysregulated in a large number of human cancers. This pathway has many diverse effects in the regulation of oncogenesis, tumor progression, differentiation, and apoptosis. Significant efforts have led to the clinical success of some MAPK-ERK pathway inhibitors. However, the clinical benefits of these inhibitors are frequently compromised by the development of drug resistance. In this Special Issue, we will publish reviews and original research that provide new insights into the MAPK/ERK signaling pathway in cancers, how it can be targeted therapeutically, and how it is possible to overcome the already observed drug resistance.

---

### Guest Editor

Dr. Duarte Pignatelli

1. Cancer Signalling & Metabolism, Instituto de Investigação e Inovação em Saúde (I3S), Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Universidade do Porto, 4200-135 Porto, Portugal
2. Department of Endocrinology, Centro Hospitalar Universitário S João, (S Joao University Hospital Center) 4200-135 Porto, Portugal.

---

### Deadline for manuscript submissions

closed (30 April 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/44863](https://mdpi.com/si/44863)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
cancers@mdpi.com

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed

---



[mdpi.com/journal/  
cancers](http://mdpi.com/journal/cancers)

## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

